Wednesday, February 18, 2026 2/18/2026

The Protein C Pathway in Mitigation of Radiation-Induced Endothelial and Vascular Dysfunction

Award Number: U01AI133561
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/05/2017
PERIOD OF PERFORMANCE END DATE: 11/30/2022

Group Awards By:

View Award Description

The Protein C Pathway in Mitigation of Radiation-Induced Endothelial and Vascular Dysfunction - PROJECT SUMMARY/ABSTRACT The threat of nuclear accidents or attacks makes it critical to develop medical countermeasures. Preclinical studies have shown a relation between vascular dysfunction and chronic organ radiation damage, but little is known about the underlying protective mechanisms. Hence, to identify targets for mitigation, research is needed to elucidate pathways involved in radiation-induced vascular dysfunction and vascular protection. Radiation-induced endothelial dysfunction is associated with detrimental alterations in the protein C pathway. Loss of endothelial surface thrombomodulin (Thbd) leads to reduced levels of activated protein C (APC), a critical component in plasma that has anticoagulant and anti-inflammatory properties and that enhances endothelial cell survival. We have previously shown that recombinant APC is an effective mitigator of acute radiation injury when administered 24 h after total-body irradiation in a mouse model. We will further explore the paradigm that the protein C pathway plays a central role in radiation-induced vascular dysfunction and that APC is an effective mitigator of both acute and late radiation toxicity in multiple organs. In vitro studies with wild-type and recombinant APC using irradiated human endothelial cells in culture will determine which structural features of APC and which endothelial APC receptors are critical for enhancing post-radiation endothelial function. In vivo studies with wild-type mice, Thbd-deficient mice, and mice with enhanced vascular responses to radiation in the small intestine, heart and brain—three organ systems critical in the endogenous levels of APC will determine the role of the Thbd–protein C pathway in both the acute and the late delayed response to radiation. Gene expression profiling focused on endothelial cells extracted from mice will identify radiation-induced changes in the translatome and the effects of APC on those gene expression profiles. Plasma samples from the same mice will be used to identify metabolite profiles indicative of radiation injury and reflective of how APC alters host responses. Such metabolic data may lead to novel biomarkers, as well as enlightening us about how radiation and radiomitigation affect various metabolic pathways. In summary, these studies will provide novel insights into mechanisms by which the Thbd–protein C pathway components, i.e., APC and its endothelial receptors, achieve endothelial radiomitigation. Studies of endothelial gene expression profiles will provide insights into which endothelial regulatory systems are significantly altered by radiation and rescued by APC. Basic knowledge from this project will provide key data required for thoughtful development of countermeasures addressing radiation-induced endovascular injury.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$42,420 )
2024	2021	UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES	4301 W MARKHAM ST	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	5	10/23/2023	NON-COMPETING CONTINUATION	-$42,420
														Subtotal = -$42,420

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	5	7/18/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $588,106 )
2021	2021	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	5	5/27/2021	NON-COMPETING CONTINUATION	$588,106
														Subtotal = $588,106

Issue Date FY: 2020 ( Subtotal = $768,154 )
2020	2020	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	4	6/3/2020	NON-COMPETING CONTINUATION	$588,106
2020	2020	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	001	4	8/18/2020	NON-COMPETING CONTINUATION	$180,048
														Subtotal = $768,154

Issue Date FY: 2019 ( Subtotal = $704,251 )
2019	2019	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	001	3	5/20/2019	NON-COMPETING CONTINUATION	$588,106
2019	2019	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	002	3	6/24/2019	NON-COMPETING CONTINUATION	$116,145
2019	2018	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	2	3/14/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $704,251

Issue Date FY: 2018 ( Subtotal = $588,106 )
2018	2018	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	2	5/10/2018	NON-COMPETING CONTINUATION	$588,106
														Subtotal = $588,106

Issue Date FY: 2017 ( Subtotal = $624,856 )
2017	2017	UNIVERSITY OF ARKANSAS SYSTEM	4301 W MARKHAM ST SLOT 812 BIO-MED BLDG 1 STE 102	LITTLE ROCK	AR	72205	PULASKI	USA	Allergy and Infectious Diseases Research	000	1	6/5/2017	NEW	$624,856
														Subtotal = $624,856

Grand Total All Awards = $3,231,053

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Protein C Pathway in Mitigation of Radiation-Induced Endothelial and Vascular Dysfunction

Award Number: U01AI133561

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/05/2017

PERIOD OF PERFORMANCE END DATE: 11/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer